The short version of obesity research fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-07 and is reviewed periodically as new material appears.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Research and public pressure have led to bans on the use of Bisphenol A in bottles and cups to be used by children. In 2008 Walmart announced that it would stop selling baby bottles and food containers containing BPA. As of 2017, these were applied in at least 40 countries. Canada classified BPA as "toxic" in 2008 under the Canadian Environmental Protection Act. In 2011 use of bisphenol A in baby bottles was forbidden in all EU countries, in China, in Malaysia, and South Africa. In July 2012, the FDA stated that BPA would no longer used in baby bottles and sippy cups, in response to a petition from the American Chemistry Council stating that this was now in line with industry practice. Other countries such as Argentina and Brazil followed suit by prohibiting bisphenol A in baby bottles. Korea has extended its BPA ban to include all children's utensils, containers and packaging as of January 2020. There are calls for increased regulation of BPA in India.
=== Read trimming === Sometimes, the raw reads produced by the sequencer are correct and precise only in a fraction of their length. Using the entire read may introduce artifacts in the downstream analyses like genome assembly, SNP calling, or gene expression estimation. Two classes of trimming programs have been introduced, based on the window-based or the running-sum classes of algorithms. This is a partial list of the trimming algorithms currently available, specifying the algorithm class they belong to:
A harmful, or deleterious, mutation decreases the fitness of the organism. Many, but not all mutations in essential genes are harmful (if a mutation does not change the amino acid sequence in an essential protein, it is harmless in most cases). A beneficial, or advantageous mutation increases the fitness of the organism. Examples are mutations that lead to antibiotic resistance in bacteria (which are beneficial for bacteria but usually not for humans). A neutral mutation has no harmful or beneficial effect on the organism. Such mutations occur at a steady rate, forming the basis for the molecular clock. In the neutral theory of molecular evolution, neutral mutations provide genetic drift as the basis for most variation at the molecular level. In animals or plants, most mutations are neutral, given that the vast majority of their genomes is either non-coding or consists of repetitive sequences that have no obvious function ("junk DNA"). Synonymous mutations, that is mutations that do not change the amino acid sequence of a protein, rarely have fitness effects, but sometimes they do. For example, the sequence of an altered mRNA can lead to an altered RNA structure or stability which may affect protein synthesis. Large-scale quantitative mutagenesis screens, in which thousands of millions of mutations are tested, invariably find that a larger fraction of mutations has harmful effects but always returns a number of beneficial mutations as well. For instance, in a screen of all gene deletions in E.
=== Cyberwarfare vs. cyber war === The term "cyberwarfare" is distinct from the term "cyber war". Cyberwarfare includes techniques, tactics and procedures that may be involved in a cyber war, but the term does not imply scale, protraction or violence, which are typically associated with the term "war", which inherently refers to a large-scale action, typically over a protracted period of time, and may include objectives seeking to utilize violence or the aim to kill. A cyber war could accurately describe a protracted period of back-and-forth cyber attacks (including in combination with traditional military action) between warring states. To date, no such action is known to have occurred. Instead, armed forces have responded with tit-for-tat military cyber actions. For example, in June 2019, the United States launched a cyber attack against Iranian weapons systems in retaliation to the shooting down of a US drone in the Strait of Hormuz.
=== St–Sz === Frank Stahl (1929–2025), US molecular biologist known for the Meselson-Stahl experiment Donald F. Steiner (1930–2014). American biochemist at the University of Chicago, who made ground breaking discoveries in the treatment of diabetes. Member Natl. Acad. Sci. USA Joan Steitz FRS (foreign associate) (b. 1941). American biochemist at Yale University, best known for her work on RNA. Member Natl. Acad. Sci. USA. Thomas A. Steitz FRS (foreign associate) (1940–2018). American biochemist at Yale University, best known for his pioneering work on the ribosome. Nobel Prize in Chemistry, 2009. Member Natl. Acad. Sci. USA. Marjory Stephenson FRS (one of the first two women elected) (1885-1948). British biochemist and microbiologist at Cambridge University, most widely remembered for her seminal book, Bacterial Metabolism. Audrey Stevens (1932–2010). American biochemist at Oak Ridge National Laboratory, co-discoverer of RNA polymerase. Member Natl. Acad. Sci. USA. Bruce Stone (1928–2008). Australian biochemist known for work in cereal and grass polysaccharides. Foundation Professor of Biochemistry at La Trobe University (1972–1993). Lubert Stryer (1938–2024). American biophysicist at Stanford who pioneered the use of fluorescence spectroscopy, particularly Förster resonance energy transfer, to monitor the structure and dynamics of biological macromolecules. He is best known for his textbook Biochemistry. Member Natl. Acad. Sci. USA. Paul K.
Sources: en.wikipedia.org
=== Light-distance === George Gamow discussed measurements of time such as the "light-mile" and "light-foot", the time taken for light to travel the specified unit distance, defined by "reversing the procedure" used in defining a light-year. A light-foot is roughly one nanosecond, and one light-mile is approximately five microseconds.
== Prevention == Prevention of atherosclerosis, which is a major risk factor of arterial embolism, can be performed e.g. by dieting, physical exercise and smoking cessation. In case of high risk for developing thromboembolism, antithrombotic medication such as warfarin or coumadin may be taken prophylactically. Antiplatelet drugs may also be needed.
Boletus edulis fruit bodies contain diverse phytochemicals, including 500 mg of ergosterol per 100 g of dried mushroom, and ergothioneine. The fruit bodies contain numerous polyphenols, especially a high content of rosmarinic acid, and organic acids (such as oxalic, citric, malic, succinic and fumaric acids), and alkaloids.
Carrier ionophores that bind to a particular ion and shield its charge from the surrounding environment. This makes it easier for the ion to pass through the hydrophobic interior of the lipid membrane. However, these ionophores become unable to transport ions under very low temperatures. An example of a carrier ionophore is valinomycin, a molecule that transports a single potassium cation. Carrier ionophores may be proteins or other molecules. Channel formers that introduce a hydrophilic pore into the membrane, allowing ions to pass through without coming into contact with the membrane's hydrophobic interior. Channel forming ionophores are usually large proteins. This type of ionophores can maintain their ability to transfer ions at low temperatures, unlike carrier ionophores. Examples of channel-forming ionophores are gramicidin A and nystatin. Ionophores that transport hydrogen ions (H+, i.e. protons) across the cell membrane are called protonophores. Iron ionophores and chelating agents are collectively called siderophores.
Sources: en.wikipedia.org
In 2007, ten people in St. Louis, Missouri developed the disease after eating imported fish. In February 2008, the U.S. Food and Drug Administration (FDA) traced several outbreaks to the Flower Garden Banks National Marine Sanctuary in the northern Gulf of Mexico, near the Texas–Louisiana shoreline. The FDA advised seafood processors that ciguatera poisoning was reasonably likely to occur from eating several species of fish caught as far as 50 miles (80 km) from the sanctuary. From August 2010 to July 2011, there were eight outbreaks of ciguatera fish poisoning in New York City. Outbreaks were linked to barracuda and grouper purchased at a fish market in Queens, New York. In the first quarter of 2012, two restaurants in Lanzarote, Canary Islands are thought to have been the source of ciguatera poisoning, leading to new fishing regulations issued 18 April 2012. The first outbreak was reported in February 2012. Diners suffered with vomiting, diarrhoea and abdominal pain several hours after eating amberjack. The second case was in early April affecting six people who live in Lanzarote and had all eaten amberjack at a local restaurant. In March 2014, nine people were hospitalised near Macksville, New South Wales, Australia after a recreational fisherman caught a 55 lb (25 kg) Spanish mackerel (Scomberomorus commersoni) off Scotts Head (NSW) and then shared it among his friends and family. In April 2015, fourteen crew members of a potash ship were hospitalized in Saint John, New Brunswick, Canada after consuming tropical fish obtained from international waters.
=== Miscellaneous === Urine drug screen — screen for usage of recreational drugs Urine cytology — cytopathological examination of cells in the urine, used to screen for cancer Urine protein electrophoresis — classification and measurement of different proteins in the urine; used to help diagnose monoclonal gammopathies Urine organic acids, urine amino acids — used to test for some inborn errors of metabolism
Progestogens, including both progesterone and progestins, are used medically in hormonal birth control, hormone therapy, to treat gynecological disorders, to suppress sex hormone levels for various purposes, and for other indications.
exaggerated neuronal reflexes triggered by stimulation of irritant receptors on sensory nerve endings (such as exercise-induced asthma) release of preformed cytokines from several type of inflammatory cells (T cells, eosinophils) in allergen-induced asthma Note: Another chemical (NPPB: 5-nitro-2(3-phenyl) propylamino-benzoic acid) was shown, in the same study, to be a more effective chloride channel blocker. Finally it may act by inhibiting calcium influx. Cromoglicate is classified as a chromone. Cromolyn is also being tested as a drug to treat insulin-induced lipoatrophy and Alzheimer's disease in combination with Ibuprofen. Cromolyn is also known to bind S100P protein and disrupt the interaction with RAGE.
=== Global and national expansion === Church's Chicken began its international expansion in the 1970s, in Canada, Mexico, Japan, and Puerto Rico. In the 1980s, it gained popularity in Indonesia when it opened under the trade name, "Texas Chicken". The first reason of changing the name to "Texas" is because the brand name "Church" was not popular in countries with majority non-Christian religions, such as Indonesia. Afterwards, locations in Malaysia, Taiwan, Singapore, and the Philippines were also opened under the trade name "Texas Chicken". In February 2008, Church's Chicken entered the UK market under the "Texas Chicken" name, claiming to have signed up 50 former Dixy Chicken franchisees. Only a small number of restaurants opened, with one in High Road Leytonstone, London, and another in Salford, Greater Manchester. They withdrew from the UK a few years later. In 2017, Church's Chicken announced a multi-year development deal with Goalz Restaurant Group, LLC to develop 20 Church's Chicken restaurants each year in Florida, Kentucky, Ohio, Colorado, North Carolina and South Carolina.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.